Immunomedics, Inc. (NASDAQ:IMMU) Expected to Post Earnings of -$0.40 Per Share
Equities analysts expect Immunomedics, Inc. (NASDAQ:IMMU) to report earnings of ($0.40) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Immunomedics’ earnings, with estimates ranging from ($0.41) to ($0.37). Immunomedics posted earnings of ($0.35) per share during the same quarter last year, which would indicate a negative year over year growth rate of 14.3%. The business is scheduled to report its next earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Immunomedics will report full year earnings of ($1.66) per share for the current year, with EPS estimates ranging from ($1.70) to ($1.60). For the next year, analysts anticipate that the firm will post earnings of ($1.48) per share, with EPS estimates ranging from ($1.72) to ($0.99). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Immunomedics.
Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.09). During the same quarter in the prior year, the business posted ($0.68) earnings per share.
Shares of IMMU traded down $0.51 during trading hours on Wednesday, reaching $13.76. The company’s stock had a trading volume of 1,905,400 shares, compared to its average volume of 2,751,142. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -13.36 and a beta of 2.10. Immunomedics has a 1-year low of $11.55 and a 1-year high of $24.99. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $14.45 and a two-hundred day moving average of $14.98.
In other news, Director Avoro Capital Advisors Llc acquired 1,000,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were purchased at an average price of $13.23 per share, for a total transaction of $13,230,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bryan Ball acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was purchased at an average price of $14.18 per share, for a total transaction of $70,900.00. Following the acquisition, the insider now directly owns 10,000 shares of the company’s stock, valued at approximately $141,800. The disclosure for this purchase can be found here. Corporate insiders own 9.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. North Star Investment Management Corp. bought a new stake in Immunomedics during the third quarter worth approximately $66,000. Atria Investments LLC bought a new stake in Immunomedics during the second quarter worth approximately $1,275,000. United Services Automobile Association boosted its position in Immunomedics by 135.6% during the second quarter. United Services Automobile Association now owns 317,992 shares of the biopharmaceutical company’s stock worth $4,411,000 after purchasing an additional 183,041 shares during the period. ClariVest Asset Management LLC bought a new stake in Immunomedics during the second quarter worth approximately $2,810,000. Finally, Boxer Capital LLC boosted its position in Immunomedics by 60.2% during the second quarter. Boxer Capital LLC now owns 6,567,000 shares of the biopharmaceutical company’s stock worth $91,084,000 after purchasing an additional 2,467,000 shares during the period. Hedge funds and other institutional investors own 88.58% of the company’s stock.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Read More: Hedge Funds – How They Work For Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.